Credit: Shutterstock
December 11, 2024 07:00 AM EST
Deals
Bioregnum
R&D
China
Pharma
FDA+

The End­points 100: The biotech in­dus­try braces for Trump 2.0

John Carroll

Editor & Founder

Big changes are afoot at the FDA in the wake of Don­ald Trump’s re­elec­tion, and there’s con­sid­er­able anx­i­ety in se­nior biotech ranks that an up­heaval …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Sum­mit says bis­pe­cif­ic miss­es over­all sur­vival in close­ly-watched lung can­cer study

Large phar­ma com­pa­nies spell out rea­sons why tar­iffs will harm US in­vest­ments 

Mer­ck, Dai­ichi Sankyo scrap FDA ap­pli­ca­tion for HER3 ADC af­ter sur­vival miss

Supreme Court to keep mulling state PBM dis­pute as US urges jus­tices to de­cline case

In­tel­lia re­ports case of liv­er tox­i­c­i­ty in AT­TR gene edit­ing study

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times